Emcure Pharmaceuticals
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Emcure Pharmaceuticals is poised for growth, driven by management's strategic focus on high-value therapeutic segments, particularly biologics and oncology, which are expected to enhance revenue streams. The company's recent performance, highlighted by a 22.8% revenue increase and margin expansion, underscores its operational excellence and successful integration of acquisitions. With international markets contributing approximately 56% of revenue, Emcure's expansion strategy is well-aligned with Vista's forecast of stable revenue growth and margins. However, potential headwinds such as rising input costs and competitive pressures in the domestic market could challenge profitability. The favorable macro environment, characterized by a supportive regulatory landscape and resilient demand for chronic therapies, further bolsters Emcure's outlook. Over the next 12-24 months, key opportunities include the successful commercialization of its semaglutide pipeline and continued scaling of its domestic business. Conversely, watchpoints include execution risks related to regulatory approvals and integration of acquisitions, which could impact growth trajectories
Why We Like This Stock
- Management's focus on high-value therapeutic segments is expected to drive revenue growth and enhance competitive positioning
- The successful integration of acquisitions and a robust R&D pipeline are likely to support margin expansion
- Favorable macro conditions and a strong international presence provide a solid foundation for future growth
Things To Watch Out For
- Rising input costs and pricing pressures in the US market may challenge profit margins
- Increased competition in the domestic market could impact pricing power and revenue stability
- Execution risks related to regulatory approvals and integration of acquisitions pose potential challenges to growth
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 6,658 | 7,896 | 9,204 | 9,882 | 11,267 |
| Profit Before Tax (Cr.) | 735 | 976 | 1,318 | 1,452 | 1,689 |
| PBT Margin | 11.0% | 12.4% | 14.3% | 14.7% | 15.0% |
| Net Profit (Cr.) | 523 | 682 | 917 | 1,008 | 1,150 |
| Earnings Per Share | 26.0 | 34.6 | 47.5 | 52.1 | 60.6 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| ICICI Securities | ▲ Buy | 2,305 | 04-Sep-2026 |
| Jeffries | ▲ Buy | 2,100 | 03-Sep-2026 |
| Axis Securities | ▲ Buy | 2,150 | 07-Aug-2026 |
| JPMorgan | ► Hold | 1,900 | 07-Aug-2026 |
| Motilal Oswal | ▲ Buy | 2,300 | 07-Aug-2026 |
| BOB Capital Markets | ▲ Buy | 1,965 | 06-May-2026 |
Company Overview
Show Company Profile
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.